Close

iBio, Inc. (IBIO) Arranges Production of IBIO-CFB03 With Caliber Biotherapeutics

Go back to iBio, Inc. (IBIO) Arranges Production of IBIO-CFB03 With Caliber Biotherapeutics

iBio Arranges Production of IBIO-CFB03 for Clinical Development With Caliber Biotherapeutics

April 27, 2015 8:31 AM EDT

NEWARK, DE -- (Marketwired) -- 04/27/15 -- iBio, Inc. (NYSE MKT: IBIO), has engaged Caliber Biotherapeutics LLC to scale-up and produce materials for clinical development of the first of iBio's proprietary anti-fibrosis products, IBIO-CFB03. Caliber's production will be used for IND-enabling toxicology studies and initial human clinical trials of IBIO-CFB03.

iBio is the exclusive worldwide licensee of the patents developed by Dr. Carol Feghali-Bostwick for therapies against fibrotic diseases. Dr. Feghali-Bostwick, the inventor of IBIO-CFB03, is collaborating with iBio for the development of various applications of her invention to address systemic sclerosis, idiopathic... More